Why the study?
It was unclear whether disparate use of TAVR among non-White patients has decreased over time and whether unequal access is driven by unequal access to high-volume hospitals.
Did ethno-racial disparities in access to transcatheter aortic valve replacement change over time?
Did ethno-racial disparities in access to transcatheter aortic valve replacement change over time?
The ethno-racial gap in TAVR utilization narrowed over time, primarily driven by increased access for non-White patients at high-volume hospitals.
Answers are grounded in this paper and cite their sources.
Supports narrowing ethno-racial TAVR disparities at high-volume hospitals; leaves open whether targeted policies drove equitable gains.
Objective: In this study we sought to evaluate whether disparate use of transcatheter aortic valve replacement (TAVR) among non-White patients has decreased over time, and if unequal access to TAVR is driven by unequal access to high-volume hospitals. Methods: From 2013 to 2017, we used the State Inpatient Database across 8 states (Ariz, Colo, Fla, Md, NC, NM, Nev, Wash) to identify 51,232 Medicare beneficiaries who underwent TAVR versus surgical aortic valve replacement. Hospitals were categorized as low- (<50 per year), medium- (50-100 per year), or high-volume (>100 per year) according to total valve procedures (TAVR + surgical aortic valve replacement). Multivariable logistic regression models with interactions were performed to determine the effect of race, time, and hospital volume on the utilization of TAVR. Further, an adjusted volume-stratified time trend analysis showed that utilization of TAVR at high volume hospitals increased faster for non-White patients versus White patients by 8.6% per year (OR, 1.09; 95% CI, 1.01-1.16) whereas use at low- and medium-volume hospitals did not contribute to any decreasing utilization gap. Conclusions: This analysis shows initial low rates of TAVR utilization among non-White patients followed by accelerated use over time, relative to White patients. This narrowing gap was driven by increased TAVR utilization by non-White patients at high-volume hospitals.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: